SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.
Business Highlights
Surrozen remains focused on its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases.
Key events in second quarter 2025
“We are encouraged by the continued momentum in our ophthalmology pipeline and the strategic steps we have taken to support their advancement,” said Craig Parker, President and Chief Executive Officer of Surrozen. “With the appointment of Dr. Daniel Chao, the formation of our Clinical Advisory Board and the issuance of a key patent supporting our multi-specific approach, we are well positioned to advance SZN-8141 and SZN-8143 toward clinical development and address critical unmet needs in retinal disease.”
Second Quarter 2025 Financial Highlights
- Cash Position: Cash and cash equivalents were $90.4 million as of June 30, 2025, compared to $101.6 million as of March 31, 2025.
- Research Service Revenue – Related Party: Research service revenue from a related party was $1.0 million for the quarter, compared to zero for the same period in 2024, driven by the collaboration with TCGFB, Inc. for TGF-β antibodies.
- Operating Expenses:
- Other Income and Expenses:
- Net Income (Loss): Net income was $39.7 million, or $2.55 per share for the quarter, compared to a net loss of $25.3 million, or ($7.99) per share, for the same period in 2024.
Surrozen’s Ophthalmology Portfolio
About SZN-8141 for retinal diseases
SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism, which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age-Related Macular Degeneration (wet AMD). The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF monotherapies. In addition, Fzd4 monotherapy has demonstrated proof of concept in DME in clinical trials. We believe SZN-8141 has the potential to treat multiple retinal vascular diseases and be differentiated from existing therapies. Data generated in preclinical models of retinal vascular diseases demonstrated that SZN-8141 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth.
About SZN-8143 for retinal diseases
SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema (UME). The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF monotherapies. In addition, Fzd4 monotherapy has demonstrated proof of concept in clinical trials for retinal disease. We believe SZN-8143 has the potential to treat multiple retinal vascular diseases and be differentiated from existing therapies. Data generated in preclinical models of retinal vascular diseases demonstrated that SZN-8143 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth.
About SZN-413 for Retinal Diseases
SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP™ technology. It is currently being developed for the treatment of retinal vascular-associated diseases. Data generated by Surrozen with SZN-413 in preclinical models of retinopathy demonstrated that SZN-413 could potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth and reduce vascular leakage. This novel approach could thus potentially allow for regeneration of healthy eye tissue, not only halting retinopathy, but possibly allowing for a full reversal of the patient’s disease.
About Surrozen
Surrozen is a biotechnology company developing tissue-specific antibodies to selectively modulate the Wnt pathway, with a current focus on ophthalmology. Its proprietary technologies aim to harness the body’s biological repair mechanisms to treat severe diseases. For more information, visit www.surrozen.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact:
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| SURROZEN, INC. Unaudited Condensed Consolidated Statements of Operations (In thousands, except per share amounts) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Research service revenue – related party | $ | 983 | $ | — | $ | 1,966 | $ | — | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 6,042 | 5,335 | 12,600 | 10,582 | ||||||||||||
| General and administrative | 3,958 | 3,714 | 7,934 | 7,597 | ||||||||||||
| Total operating expenses | 10,000 | 9,049 | 20,534 | 18,179 | ||||||||||||
| Loss from operations | (9,017 | ) | (9,049 | ) | (18,568 | ) | (18,179 | ) | ||||||||
| Interest income | 1,025 | 490 | 1,321 | 875 | ||||||||||||
| Loss on issuance of common stock, pre-funded warrants and warrants in the 2024 PIPE | — | (20,397 | ) | — | (20,397 | ) | ||||||||||
| Loss on amendment and cancellation of warrants | — | — | (2,073 | ) | — | |||||||||||
| Loss on execution of the 2025 PIPE | — | — | (71,084 | ) | — | |||||||||||
| Gain on change in fair value of tranche liability | 31,520 | — | 47,860 | — | ||||||||||||
| Gain on settlement of tranche liability | — | — | 1,117 | — | ||||||||||||
| Other income, net | 16,218 | 3,695 | 54,203 | 3,610 | ||||||||||||
| Net income (loss) | $ | 39,746 | $ | (25,261 | ) | $ | 12,776 | $ | (34,091 | ) | ||||||
| Net income (loss) available to (attributable to) common stockholders, basic and diluted | $ | 21,808 | $ | (25,261 | ) | $ | 5,210 | $ | (34,091 | ) | ||||||
| Net income (loss) per share available to (attributable to) common stockholders, basic and diluted | $ | 2.55 | $ | (7.99 | ) | $ | 0.85 | $ | (13.00 | ) | ||||||
| Weighted-average shares used in computing net income (loss) per share available to (attributable to) common stockholders, basic and diluted | 8,541 | 3,162 | 6,098 | 2,622 | ||||||||||||
| SURROZEN, INC. Condensed Consolidated Balance Sheets (In thousands) | ||||||||
| June 30, | December 31, | |||||||
| 2025 | 2024(1) | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 90,390 | $ | 34,565 | ||||
| Accounts receivable | 2,317 | 2,039 | ||||||
| Accounts receivable – related party | 252 | 502 | ||||||
| Prepaid expenses and other current assets | 1,276 | 1,826 | ||||||
| Total current assets | 94,235 | 38,932 | ||||||
| Property and equipment, net | 176 | 562 | ||||||
| Operating lease right-of-use assets | 6,900 | 7,801 | ||||||
| Restricted cash | 688 | 688 | ||||||
| Warrant asset | 615 | 153 | ||||||
| Other assets | 82 | 331 | ||||||
| Total assets | $ | 102,696 | $ | 48,467 | ||||
| Liabilities and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 354 | $ | 306 | ||||
| Accrued and other liabilities | 4,191 | 5,180 | ||||||
| Lease liabilities, current portion | 1,198 | 1,829 | ||||||
| Total current liabilities | 5,743 | 7,315 | ||||||
| Lease liabilities, noncurrent portion | 6,316 | 6,640 | ||||||
| Tranche liability | 10,903 | — | ||||||
| Warrant liabilities | 32,620 | 55,892 | ||||||
| Total liabilities | 55,582 | 69,847 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 1 | — | ||||||
| Additional paid-in-capital | 319,596 | 263,879 | ||||||
| Accumulated deficit | (272,483 | ) | (285,259 | ) | ||||
| Total stockholders’ equity (deficit) | 47,114 | (21,380 | ) | |||||
| Total liabilities and stockholders’ equity | $ | 102,696 | $ | 48,467 | ||||
(1) Derived from the audited consolidated financial statements, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.
| Last Trade: | US$9.64 |
| Daily Change: | 0.08 0.84 |
| Daily Volume: | 1,151 |
| Market Cap: | US$82.520M |
August 06, 2025 March 31, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
